Associations between CMS's Clinical Performance Measures project benchmarks, profit structure, and mortality in dialysis units

Kidney International

Volumn 69, Issue 11, 2006, Pages 2094-2100

  Szczech, L A ^a,b   Klassen, P S ^b,c   Chua, B ^d   Hedayati, S S ^e   Flanigan, M ^f   McClellan, W M ^g   Reddan, D N ^a,h   Rettig, R A ⁱ   Frankenfield, D L ^j   Owen, W F ^k  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AMGEN INC   (United States)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NATIONAL UNIVERSITY OF IRELAND   (Ireland)

ⁱ RAND CORPORATION   (United States)

^j CENTERS FOR MEDICARE AND MEDICAID SERVICES   (United States)

^k UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

more..

Author keywords

Economics; End stage renal disease; Medicare; Mortality; Outcomes

Indexed keywords

SERUM ALBUMIN; TRANSFERRIN; UREA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEMATOCRIT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; PROFIT; QUALITY CONTROL; SURVIVAL;

AMBULATORY CARE FACILITIES; BENCHMARKING; FEMALE; FOLLOW-UP STUDIES; HEMODIALYSIS UNITS, HOSPITAL; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PRIVATE SECTOR; PUBLIC SECTOR; RENAL DIALYSIS;

EID: 33745278005     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000267     Document Type: Article

References (24)

1. US Renal Data System. USRDS 2003 Annual Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2003.
2. MedPac Report. Available at http://www.medpac.gov (accessed 11/2/04).
3. Relman AS, Rennie D. Treatment of end-stage renal disease: free but not equal. N Engl J Med 1980; 303: 996-998.
4. Devereaux PJ, Schunemann HJ, Ravindran N et al. Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers. J Am Med Assoc 2002; 288: 2449-2457.
5. Garg PP, Frick KD, Diener-West M, Powe NR. Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation. N Engl J Med 1999; 341: 1653-1660.
6. Port FK, Wolfe RA. Ownership of dialysis facilities and patients' survival. N Eng J Med 2000; 342: 1053.
7. Irvin RA. Ownership and mortality in the dialysis industry: multivariate regression analysis. In: Irvin RA (eds). Quality of Care, Asymmetric Information, and Patient Outcomes in US For-Profit and Not-For-Profit Renal Dialysis Facilities [dissertation]. Washington University: St Louis, MO, 1988, pp 55-80.
8. Irvin RA. Ownership and mortality in the dialysis industry: propensity score analysis. In: Irvin RA (ed). Quality of Care, Asymmetric Information, and Patient Outcomes in US For-Profit and Not-For-Profit Renal Dialysis Facilities [dissertation]. Washington University: St Louis, MO, 1988 pp 81-107.
9. Irvin RA. Quality of care differences by ownership in United States renal dialysis facilities. ASAIO J 2000; 46: 775-778.
10. Farley DO. Effects of Competition on Dialysis Facility Service Levels and Patient Selection [dissertation]. RAND: Santa Monica, CA, 1993.
11. McClellan WM, Soucie JM, Flanders WD. Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. J Am Soc Nephrol 1998; 9: 1940-1947.
12. Held PJ, Garcia JR, Pauly MV, Cahn MA. Price of dialysis, unit staffing, and length of dialysis treatments. Am J Kidney Dis 1990; 15: 441-450.
13. NKF-K/DOQI hemoDialysis adequacy Work Group. Am J Kidney Dis 2001; 37(Suppl 1): 7-65.
14. Owen Jr WF, Lew NL, Liu Y et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Eng J Med 1993; 329: 1001-1006.
15. Health Care Financing Administration. Annual Report, End Stage Renal Disease Core Indicators Project, Department of Health and Human Services. Health Care Finance Administration: Baltimore, MD, 1999.
16. McClellan WM, Frederick PR, Helgerson SD et al. Data driven approach to improving care of in-center hemodialysis patients. Health Care Fin Rev 1995; 16: 129-140.
17. Nissenson AR, Owen WF. Ownership of dialysis facilities and patients' survival. N Engl J Med 2000; 342: 1054-1055.
18. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458.
19. Owen WF, Chertow G, Lazarus JM, Lowrie EG. The dose of hemodialysis: mortality responses by race and gender. J Am Med Assoc 1998; 280: 1764-1768.
20. Kaysen GA, Chertow GM, Adhikarla R et al. Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 2001; 60: 333-340.
21. Welch HG, Wennberg DE, Welch WP. The use of Medicare home health care services. N Engl J Med 1996; 335: 324-329.
22. Steinberg EP, Eknoyan G, Levin N et al. Methods used to evaluate the quality of evidence underlying the National Kidney Foundation-Dialysis Outcomes & Quality Initiative Practice Guidelines: description, findings and implications. Am J Kidney Dis 2000; 36: 1-11.
23. Sugarman JR, Frederick PR, Frankenfield DL et al. Developing clinical performance measures based on the Dialysis Outcomes Quality Initiative clinical practice guidelines: process, outcomes, and implications. Am J Kidney Dis 2003; 42: 806-812.
24. Clase CM, St Pierre MW, Churchill DN. Conversion between bromcresol green- and bromcresol purple-measured albumin in renal disease. Nephrol Dial Transplant 2001; 16: 1925-1929.